Emmecell is pioneering a novel approach to regenerative medicine through its proprietary Magnetic Cell Delivery technology, which addresses the critical challenges of delivering, retaining, and integrating cell therapies into target tissues. This platform utilizes magnetic nanoparticles to effectively localize and maintain cell therapies at the desired site, enhancing their potential for successful integration into the host tissue. Emmecell's focus is primarily on ophthalmic applications, particularly in treating conditions such as corneal edema, where traditional surgical options are limited and often invasive.

The company's lead product candidate, EO2002, involves the use of magnetic human corneal endothelial cells to provide a non-surgical alternative for patients suffering from corneal edema. This innovative treatment aims to replace the need for complex surgical procedures, offering a safer and more effective solution for restoring vision in patients with advanced corneal conditions. Emmecell's commitment to advancing regenerative medicine is underscored by its extensive intellectual property portfolio and ongoing clinical trials, which are designed to validate the efficacy and safety of its cell-based therapies.

United States

Emmecel - Emmetrope Ophthalmics LLC, (aka “Emmecell”) is a privately-held, clinical stage biotechnology company developing cell-based therapies. Emmecell’s platform technology leverages magnetic nanoparticles to effectively localize and integrate cell therapies to the appropriate target tissue. Our lead product EO2002 is a cell therapy for treatment for corneal edema, the most common indication for corneal transplantation. Cell Manufacturing and Production LLC (CellMP) was founded in 2018 and is a subsidiary of Emmecell providing GMP manufacturing services in Menlo Park, CA.

Emmecell

Company Details